Drug Trial Radar · NCT07281495
Taldefgrobep Alfa in Adults With Overweight and Obesity
Last checked: Nov 19, 2026Latest source record: Mar 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Nov 24, 2025
Primary completion
Sep 2026
Study completion Sep 2026
Sponsor
- Lead sponsor
- Biohaven Therapeutics Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 15, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, double-blind, placebo-controlled, multiple dose study to evaluate the efficacy, safety, and tolerability of taldefgrobep alfa in adults with overweight and obesity, with an open-label extension.
Conditions
- Obesity
- Overweight
Interventions
Taldefgrobep AlfaDrug
Subcutaneous injection administered once each week
PlaceboDrug
Subcutaneous injection (matching placebo) administered once each week
Taldefgrobep AlfaDrug
Subcutaneous injection administered once every 4 weeks
PlaceboDrug
Subcutaneous injection (matching placebo) administered once every 4 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent change in total body weight from Baseline to Week 24Time frame: Baseline to Week 24
Locations
20 sites in 1 country. Site status is shown where the registry gives one.
Site-001
Chula Vista, California
Site-014
Montclair, California
Site-011
Sacramento, California
Site-018
Tustin, California
Site-020
Orlando, Florida
Site-008
Palm Springs, Florida
Site-015
St. Petersburg, Florida
Site-007
Chicago, Illinois
Site-016
Indianapolis, Indiana
Site-010
Baton Rouge, Louisiana
Site-009
Metairie, Louisiana
Site-006
City of Saint Peters, Missouri
Site-003
Springfield, Missouri
Site-019
Monroe, North Carolina
Site-002
Fargo, North Dakota
Site-017
North Charleston, South Carolina
Site-005
Austin, Texas
Site-012
McKinney, Texas
Site-013
San Antonio, Texas
Site-004
Arlington, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.